The company's biggest revenue increase this quarter came from its diagnostics and genomics group, though its other businesses also posted increases.
The company said revenues from its non-invasive heart transplant rejection test AlloMap rose about 16 percent year over year.
During an earnings call, company executives discussed plans to grow reimbursement of new tests, stabilize pricing, and save costs through a number of projects.
The company also launched a clinical genomics service, offering newborn screening and high-throughput NSG for rare inherited diseases.
The company missed analyst estimates on its top line, but beat analyst estimates for adjusted earnings per share and raised its adjusted EPS guidance for FY 2017.
The company credited its molecular diagnostics and international businesses as drivers of new growth.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The company, which beat analyst estimates on both the top and bottom lines, said completed Cologuard test volume rose 149 percent to 135,000 tests.
The change comes amid lower than expected revenues for the first half of this year, as well as an anticipated continued lack of reimbursement coverage in the US.
The firm said today that it received a notice that it is out of compliance with a rule requiring timely filings with the US Securities and Exchange Commission.
The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.
A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.
Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.